FDA staff questions Sanofi bird flu vaccine

WASHINGTON Mon Feb 26, 2007 11:24am EST

A worker handles vials of medicine in a laboratory of pharmaceutical company Sanofi Aventis in Ambares near Bordeaux, France, September 20, 2006. Data on Sanofi-Aventis's experimental bird flu vaccine shows higher doses worked better, but it is unclear whether those results prove the product's effectiveness, U.S. regulatory staff said in documents released on Monday. REUTERS/Regis Duvignau

A worker handles vials of medicine in a laboratory of pharmaceutical company Sanofi Aventis in Ambares near Bordeaux, France, September 20, 2006. Data on Sanofi-Aventis's experimental bird flu vaccine shows higher doses worked better, but it is unclear whether those results prove the product's effectiveness, U.S. regulatory staff said in documents released on Monday.

Credit: Reuters/Regis Duvignau

Related Topics

WASHINGTON (Reuters) - Data on Sanofi-Aventis's (SNY.N) (SASY.PA) experimental bird flu vaccine shows higher doses worked better, but it is unclear whether those results prove the product's effectiveness, U.S. regulatory staff said in documents released on Monday.

Food and Drug Administration staff also said studies of the vaccine, which targets the potentially pandemic H5N1 strain of the influenza virus, showed "no significant safety signals."

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.